VivoSim Labs Inc (VIVS) Stock AnalysisVIVSStock AnalysisVivoSim Labs Inc

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models. It operates in the Healthcare sector.

VivoSim Labs Inc (VIVS) is not a good buy right now. The current price is $0.29, and the stock has experienced a staggering year-to-date change of -84.82%. Additionally, the RSI is at 33.47, indicating that the stock is in a potentially oversold condition, but this does not outweigh the significant risks. The company is facing ongoing financial struggles with a negative net income of -$5,764,000 in Q4 2026 and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the company's declining revenue, with a 20-day change of -17.21% and a projected trajectory showing a potential increase of only +25.85%, which is insufficient to recover from its current low valuation.